AIM ImmunoTech Inc.

AIM Healthcare Biotechnology

AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024. In the quarter to June 2026, revenue grew 4.00%, EPS grew 94.0% and free cash flow fell 167.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.17 0.00 0.00%
Market cap
$6.8M
P/E
0.0×
Fwd P/E
−0.6×
Dividend yield
—
F-score
3/9
Altman Z
−113.91
Beneish M
n/a
Dividend safety
n/a

AIM ImmunoTech Inc. (AIM) P/E ratio

Alert me on P/E ratio

AIM ImmunoTech Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 25.6× (May 2020) — the current reading is the lowest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
41 more quarters

Against its own ten years

Low 0.0× High 25.6×
Ten-year median 0.0×
Current reading's percentile 94

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AIM